COYA
Coya Therapeutics, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
4.87
▲ 0.01 (0.21%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
4.90
Prev close
4.86
Day high
4.95
Day low
4.81
Volume
70.85K
Market cap
—
P/E (TTM)
—
52W range
3.71 – 7.75
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+1.67%
+3.0%
1M
+11.19%
+7.5%
3M
+0.62%
-2.5%
6M
+5.64%
-5.4%
YTD
-16.03%
-28.3%
1Y
-20.81%
-40.8%
3Y
+40.96%
-33.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.95M | $3.55M | $6.00M | $0 | — | +123.6% |
| Operating revenue | $7.95M | $3.55M | $6.00M | $0 | — | +123.6% |
| Research & development | $19.02M | $11.89M | $6.04M | $4.94M | — | +60.0% |
| Selling, general & admin | $11.45M | $8.89M | $7.83M | $4.85M | — | +28.9% |
| Total operating expense | $30.50M | $20.80M | $13.91M | $9.81M | — | +46.6% |
| Operating income | -$22.56M | -$17.25M | -$7.90M | -$9.81M | — | -30.8% |
| Net interest income | — | — | — | — | $0 | — |
| Pre-tax income | -$21.22M | -$15.60M | -$7.26M | -$12.24M | — | -36.0% |
| Tax provision | $3.09K | -$720.29K | $723.85K | $0 | — | +100.4% |
| Net income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | — | -42.6% |
| Net income to common | -$21.23M | -$14.88M | -$7.99M | -$12.24M | — | -42.6% |
| Basic EPS | -1.27 | -0.98 | -0.79 | -4.73 | — | -29.6% |
| Diluted EPS | -1.27 | -0.98 | -0.79 | -4.73 | — | -29.6% |
| EBIT | -$22.56M | -$17.25M | -$7.90M | -$9.81M | — | -30.8% |
| EBITDA | -$22.53M | -$17.22M | -$7.88M | -$9.78M | — | -30.8% |
| Basic shares | 16.73M | 15.24M | 10.16M | 2.59M | — | +9.8% |
| Diluted shares | 16.73M | 15.24M | 10.16M | 2.59M | — | +9.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $46.82M | $38.34M | $32.63M | $5.93M | +22.1% |
| Cash & short-term investments | $46.82M | $38.34M | $32.63M | $5.93M | +22.1% |
| Total current assets | $49.94M | $44.31M | $41.20M | $7.18M | +12.7% |
| Property, plant & equipment | $11.23K | $38.59K | $65.95K | $93.31K | -70.9% |
| Total assets | $49.95M | $44.35M | $41.26M | $8.40M | +12.6% |
| Total current liabilities | $5.87M | $3.82M | $5.05M | $3.82M | +53.5% |
| Long-term debt | — | — | — | $12.97M | — |
| Total debt | — | — | — | $12.97M | — |
| Total liabilities | $6.92M | $4.77M | $5.63M | $16.79M | +45.1% |
| Retained earnings | -$61.96M | -$40.74M | -$25.86M | -$17.87M | -52.1% |
| Shareholder equity | $43.03M | $39.58M | $35.64M | -$8.39M | +8.7% |
| Working capital | $44.07M | $40.48M | $36.14M | $3.36M | +8.9% |
| Net tangible assets | $43.03M | $39.58M | $35.64M | -$8.39M | +8.7% |
| Shares issued | 20.93M | 16.71M | 14.41M | 9.68M | +25.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | — | -42.6% |
| Depreciation & amortisation | $27.36K | $27.36K | $27.36K | $27.36K | — | 0.0% |
| Stock-based compensation | $4.29M | $2.66M | $872.25K | $207.35K | — | +61.1% |
| Change in working capital | $3.88M | $1.88M | -$4.64M | $751.84K | — | +106.8% |
| Operating cash flow | -$10.74M | -$10.29M | -$11.19M | -$7.24M | — | -4.4% |
| Capital expenditure | — | — | — | — | -$136.80K | — |
| Investing cash flow | -$1.16M | -$25.00K | -$543.19K | -$525.00K | — | -4,558.4% |
| Financing cash flow | $20.39M | $16.03M | $38.43M | $9.36M | — | +27.2% |
| Free cash flow | -$10.74M | -$10.29M | -$11.19M | -$7.24M | — | -4.4% |
| End cash position | $46.82M | $38.34M | $32.63M | $5.93M | — | +22.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $251.15K | $3.96M | $3.56M | $163.62K | $257.88K | -93.7% |
| Operating revenue | $251.15K | $3.96M | $3.56M | $163.62K | $257.88K | -93.7% |
| Research & development | $4.11M | $6.71M | $3.43M | $3.66M | $5.21M | -38.8% |
| Selling, general & admin | $3.78M | $3.27M | $2.56M | $2.91M | $2.71M | +15.7% |
| Total operating expense | $7.89M | $9.99M | $6.00M | $6.58M | $7.93M | -21.0% |
| Operating income | -$7.64M | -$6.03M | -$2.43M | -$6.41M | -$7.68M | -26.7% |
| Pre-tax income | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -26.3% |
| Tax provision | $0 | — | — | $0 | $0 | — |
| Net income | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -26.2% |
| Net income to common | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -26.2% |
| Basic EPS | -0.32 | — | -0.13 | -0.36 | -0.44 | — |
| Diluted EPS | -0.32 | — | -0.13 | -0.36 | -0.44 | — |
| EBIT | -$7.64M | -$6.03M | -$2.43M | -$6.41M | -$7.68M | -26.7% |
| EBITDA | -$7.64M | -$6.02M | -$2.43M | -$6.41M | -$7.67M | -26.8% |
| Basic shares | 22.64M | — | 16.73M | 16.72M | 16.72M | — |
| Diluted shares | 22.64M | — | 16.73M | 16.72M | 16.72M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.72M | $46.82M | $28.13M | $29.76M | $35.53M | +8.3% |
| Cash & short-term investments | $50.72M | $46.82M | $28.13M | $29.76M | $35.53M | +8.3% |
| Total current assets | $53.26M | $49.94M | $32.02M | $33.43M | $38.37M | +6.7% |
| Property, plant & equipment | $8.42K | $11.23K | $18.07K | $24.91K | $31.75K | -25.0% |
| Total assets | $53.27M | $49.95M | $32.04M | $33.45M | $38.40M | +6.6% |
| Total current liabilities | $3.55M | $5.87M | $3.67M | $4.50M | $4.34M | -39.6% |
| Total liabilities | $4.30M | $6.92M | $4.76M | $5.14M | $5.04M | -37.9% |
| Retained earnings | -$69.17M | -$61.96M | -$56.25M | -$54.14M | -$48.04M | -11.6% |
| Shareholder equity | $48.97M | $43.03M | $27.28M | $28.31M | $33.37M | +13.8% |
| Working capital | $49.72M | $44.07M | $28.36M | $28.93M | $34.03M | +12.8% |
| Net tangible assets | $48.97M | $43.03M | $27.28M | $28.31M | $33.37M | +13.8% |
| Shares issued | 23.46M | 20.93M | 16.74M | 16.72M | 16.72M | +12.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -26.2% |
| Depreciation & amortisation | $2.81K | $6.84K | $6.84K | $6.84K | $6.84K | -59.0% |
| Stock-based compensation | $2.20M | $1.10M | $1.07M | $1.04M | $1.08M | +98.9% |
| Change in working capital | -$1.21M | $1.82M | -$608.50K | -$720.87K | $3.39M | -166.6% |
| Operating cash flow | -$6.21M | -$1.01M | -$1.13M | -$5.77M | -$2.83M | -516.5% |
| Investing cash flow | -$885.00K | -$648.61K | -$516.00K | $0 | $0 | -36.4% |
| Financing cash flow | $11.00M | $20.35M | $19.14K | $0 | $19.14K | -46.0% |
| Free cash flow | -$6.21M | -$491.13K | -$1.65M | -$5.77M | -$2.83M | -1,164.1% |
| End cash position | $50.72M | $46.82M | $28.13M | $29.76M | $35.53M | +8.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.79
+1.71% from price
SMA 20
4.56
+6.77% from price
SMA 50
4.87
+0.03% from price
SMA 100
4.67
+4.30% from price
SMA 200
4.92
-1.00% from price
EMA 12
4.76
+2.28% from price
EMA 26
4.71
+3.32% from price
EMA 50
4.73
+2.94% from price
RSI (14)
54.9
Neutral
MACD (12,26,9)
0.05
Hist 0.06
ATR (14)
0.22
4.51% of price
Realised vol 30D
54.6%
Annualised
Bollinger upper
5.19
20, 2σ
Bollinger lower
3.93
20, 2σ
50 / 200 cross
Death
4.87 vs 4.92
Trend bias
Below 200
-1.00%
Risk profile
Beta vs SPY
1.44
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
54.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.6%
Peak to trough
Max drawdown 5Y
-62.9%
Peak to trough
ATR 14
0.22
4.51% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Business Wire · 12d ago
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Zacks · 53d ago
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Business Wire · 66d ago
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Business Wire · 69d ago
Coya Therapeutics Says Phase 2 ALS Study Enters Blinded Extension Phase
MT Newswires · 75d ago
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Business Wire · 76d ago
Roth Capital Initiates Coverage on Coya Therapeutics With Buy Rating, $12 Price Target
MT Newswires · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.